Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab

ASH 2012

8 - 11 Dec 2012

Published: 13 Dec 2012

Views: Too Many Requests (UARL2)

Rating:

Save

Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA

Prof Jan Burger presents data at an ASH 2012 press conference on the combination of the novel investigational agent ibrutinib with an established therapeutic antibody, rituximab, may present a safer and more effective option than the current standard chemotherapy-based treatment regimen for patients with high-risk CLL.

Related Videos

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients

Dr Prashant Mehta - Amrita Hospital, Karala, India

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients ( Dr Prashant Mehta - Amrita Hospital, Karala, India )

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India

Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India

Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia

Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia ( Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany )

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Relapsed refractory multiple myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed refractory multiple myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Multiple myeloma (A cancer arising from plasma cells)

Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal

Multiple myeloma (A cancer arising from plasma cells) ( Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal )

More from ecancer